APL-3007 Multidose
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for APL-3007 Multidose, covering 2026-03-30 to 2026-03-30. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio [Phase 2]